CervoMed officer granted 30,000 stock options

CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options.

Rhea-AI Filing Summary

CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options. On February 11, 2026, he was awarded options to acquire 30,000 shares of CervoMed common stock at an exercise price of $4.8 per share.

The award vests in 36 roughly equal monthly installments, with vesting starting on February 28, 2026 and continuing on the last calendar day of each month over three years. All 30,000 derivative securities are reported as directly owned following this grant.

Insights

Equity Compensation Analyst

Routine officer stock option grant with time-based vesting.

CervoMed granted Chief Commercial and Business Officer Matthew Winton stock options for 30,000 shares at an exercise price of $4.8 per share. The filing classifies this as an acquisition under a grant or award, not an open-market purchase.

The options vest in 36 monthly installments starting on February 28, 2026, creating a three-year incentive period that aligns continued service with potential equity upside. All 30,000 options are reported as held directly after the transaction, indicating a straightforward, single-holder grant.

This appears to be standard executive equity compensation. Its real impact depends on CervoMed’s future share performance and Winton’s tenure, which will determine the ultimate value realized from the award.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Winton Matthew

Role Chief Commercial and Business

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

FAQ

What insider transaction did CervoMed Inc. (CRVO) report for Matthew Winton?

CervoMed reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options for 30,000 shares on February 11, 2026. These options allow him to buy CervoMed common stock at a fixed exercise price of $4.8 per share.

What are the key terms of Matthew Winton’s CervoMed (CRVO) stock option grant?

The grant covers 30,000 stock options with an exercise price of $4.8 per share. The filing shows the options were awarded at a cost of $0 per option, reflecting a typical executive equity compensation grant rather than an open-market share purchase.

How do Matthew Winton’s CervoMed (CRVO) stock options vest over time?

The options vest in 36 equal monthly installments, starting on February 28, 2026. Vesting occurs on the last calendar day of each month over a three-year period, gradually making more of the 30,000 underlying shares available for potential exercise.

How many CervoMed (CRVO) derivative securities does Matthew Winton own after this grant?

After the reported transaction, 30,000 derivative securities (stock options) are beneficially owned by Matthew Winton. The filing shows these options as held with direct ownership, meaning they are attributed personally to him rather than through an intermediary entity.

Does the CervoMed (CRVO) filing indicate whether this was a stock option purchase or a grant?

The transaction is coded as “A” for a grant, award, or other acquisition, and the price of the derivative security is listed as $0. This indicates an executive stock option grant, not an open-market purchase of CervoMed shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winton Matthew

(Last) (First) (Middle)

C/O CERVOMED INC.

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial and Business

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.8	02/11/2026		A		30,000		(1)	02/11/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.